Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at ReportsnReports.com

Dallas, Texas (PRWEB) October 10, 2013

Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several other conditions and had $ 2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of ~$ 21b in 2012.

Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report Therapy Class Overview: Rituximab biosimilar – http://www.reportsnreports.com/reports/269204-therapy-class-overview-rituximab-biosimilar.html , we have analyzed the market opportunity of rituximab biosimilar.

What one would get if buy this report:

This entry was posted in Online Marketing and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply